Gilead Sciences, Inc.
NEWS
Yet another busy week for clinical trial news. Here’s a look.
The upcoming changes will be less disruptive but will have far-reaching consequences throughout the pharmaceutical supply chain.
AT-527, an oral direct-acting antiviral agent that blocks viral RNA polymerase needed for viral replication, failed to meet its primary endpoint in the Phase II MOONSONG study.
CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.
If authorized, it could be available in the U.S. before the end of the year. It is also working to submit applications to other regulators worldwide.
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
JOBS
IN THE PRESS